retatrutide clinical trial status Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation Retatrutide Results: 28.3% Weight Loss

It remains unlicensed, unavailable outside authorised clinical trials, and prohibited under WADA and UKAD anti-doping rules

Per Sunlight's Terms of Use: once a prescription - first or refill - has been written and sent to the pharmacy, that order is not refundable

Patients need medical evaluation to determine whether they have MASLD, MASH, fibrosis, cirrhosis risk, or another liver condition

Researchers study SS-31 for its potential interactions with cardiolipin and mitochondrial membrane function in preclinical models

Effects of Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 on the Reinstatement of Cocaine-Mediated Conditioned Place Preference in Mice